Genetic predisposition and screening in pediatric cancer

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1393-1413

  Pakakasama, Samart ^a   Tomlinson, Gail E ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ATM PROTEIN; PROTEIN; PROTEIN P53; PROTEIN RET; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR PAX6; UNCLASSIFIED DRUG; WT1 PROTEIN;

AMINO ACID SUBSTITUTION; ATAXIA TELANGIECTASIA; BECKWITH WIEDEMANN SYNDROME; BLM GENE; BLOOM SYNDROME; BRAIN TUMOR; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME 11P; CHROMOSOME 13Q; CHROMOSOME BREAKAGE; COST EFFECTIVENESS ANALYSIS; DESMOID TUMOR; DEVELOPMENTAL DISORDER; FAMILIAL CANCER; FAMILIAL POLYPOSIS; GARDNER SYNDROME; GENE CLUSTER; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HEPATOBLASTOMA; HSNF5 GENE; HUMAN; INII GENE; LINKAGE ANALYSIS; MELANOMA; MENIN GENE; MISSENSE MUTATION; MULTIPLE ENDOCRINE ADENOMATOSIS; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; OSTEOSARCOMA; PENETRANCE; PERLMAN SYNDROME; RETINOBLASTOMA; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; SCREENING TEST; SECOND CANCER; SEQUENCE ANALYSIS; SIMPSON GOLABI BEHMEL SYNDROME; SIPPLE SYNDROME; SOFT TISSUE CANCER; SOLID TUMOR; THYROID CARCINOMA; VHL GENE; VON HIPPEL LINDAU DISEASE;

GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MASS SCREENING; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; RISK FACTORS;

EID: 0036977429     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00095-0     Document Type: Review

References (119)

1. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
2. Draper GJ, Sanders BM, Brownbill PA, et al. Patterns of risk of hereditary retinoblastoma and applications to genetic counseling. Br J Cancer 1992;66:211-9.
3. Sippel KC, Faioli RE, Smith GD, et al. Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet 1998;62:610-9.
4. Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999;17:1829-37.
5. Gallie BL, Ellsworth RM, Abramson DH, et al. Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation? Br J Cancer 1982;45:513-21.
6. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-6.
7. DiCiommo D, Gallie B, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol 2000;10:255-69.
8. Yandell DW, Campbell TA, Dayton SH, et al. Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. N Engl J Med 1989;321:1689-95.
9. Liu Z, Song Y, Bia B, et al. Germline mutations in the RB1 gene in patients with hereditary retinoblastoma. Genes Chromosomes Cancer 1995;14:277-84.
10. Blanquet V, Turleau C, Gross-Morand MS, et al. Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non-hereditary retinoblastoma. Hum Mol Genet 1995;4:383-8.
11. Sakai T, Ohtani N, McGee TL, et al. Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 1991;353:83-6.
12. Onadim Z, Hogg A, Baird PN, et al. Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. Proc Natl Acad Sci U S A 1992;89:6177-81.
13. Bremner R, Du DC, Connolly-Wilson MJ, et al. Deletion of RB exon 24 and 25 causes low-penetrance retinoblastoma. Am J Hum Genet 1997;61:556-70.
14. Schubert EL, Strong LC, Hansen MF. A splicing mutation in RB1 in low penetrance retinoblastoma. Hum Genet 1997;100:557-63.
15. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-71.
16. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:112-28.
17. Wong FL, Boice JD, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 1997;278:1262-7.
18. Li FP, Abramson DH, Tarone RE, et al. Hereditary retinoblastoma, lipoma and second primary cancers. J Natl Cancer Inst 1997;89:83-4.
19. Wiggs JL, Dryja TP. Predicting the risk of hereditary retinoblastoma. Am J Ophthalmol 1988;106:346-51.
20. Wiggs JL, Nordenskjold M, Yandell D, et al. Prediction of the risk of hereditary retinoblastoma, using DNA polymorphisms within the retinoblastoma gene. N Engl J Med 1988;318:151-7.
21. Moll AC, Imhof SM, Schouten-Van Meeteren YN, et al. At what age could screening for familial retinoblastoma be stopped? A register based study 1945-98. Br J Ophthalmol 2000;84:1170-2.
22. Knudson AG, Strong LC. mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972;48:313-24.
23. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatric Pathology 1990;10:1-36.
24. Francke U, Holmes LB, Atkins L, et al. Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13. Cytogenet Cell Genet 1979;24:185-92.
25. Ton CC, Hirvonen H, Miwa H, et al. Positional cloning and characterization of a paired box and homeobox containing gene from the aniridia region. Cell 1991;67:1059-74.
26. Gronskov K, Olsen JH, Sand A, et al. Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia. Hum Genet 2001;109:11-8.
27. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
28. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms tumor suppressor gene are associated with urogenital development in Denys-Drash syndrome. Cell 1991;67:437-47.
29. Li FP, Breslow NE, Morgan JM, et al. Germline WT1 mutations in Wilms' tumor patients: preliminary results. Med Pediatr Oncol 1996;27:404-7.
30. Perlman M, Goldberg GM, Bar-Ziv J, et al. Renal hamartomas and nephroblastomatosis with fetal gigantism: a familial syndrome. J Pediatr 1973;83:414-8.
31. Henneveld HT, van Lingen RA, Hamel BCJ, et al. Perlman syndrome: four additional cases and review. Am J Med Genet 1999;86:439-46.
32. Beckwith JB. Macroglossia, omphalocele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly. Birth Defects 1969;5:188-96.
33. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998;132:398-400.
34. DeBaun MR, Seigel MJ, Choyke PL. Nephromegaly in infancy and early childhood: a risk factor for Wilms tumor in Beckwith-Wiedemann syndrome. J Pediatr 1998;132:401-4.
35. Porteus MH, Norkool P, Neuberg D, et al. Characteristics and outcome of children with Beck-with-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2000;18:2026-31.
36. Pettenati MJ, Haimes JL, Higgins RR, et al. Wiedemann -Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet 1986;74:143-54.
37. KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet 1999;36:518-23.
38. Lee MP, DeBaun MR, Mitsuya K, et al. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc Natl Acad Sci U S A 1999;96:5203-8.
39. Hughes-Benzie R, Hunter AGW, Allanson JE, et al. Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet 1992;43:428-35.
40. Hughes-Benzie RM, Pilia G, Xuan JY, et al. Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. Am J Med Genet 1996;66:227-34.
41. Breslow N, Olsen J, Moksness J, et al. Familial Wilms' tumor: a descriptive study. Med Pediatr Oncol 1996;27:398-403.
42. Rahman N, Arbour L, Tonin P, et al. Evidence for a familial Wilms tumour gene (FWT1) on chromosome 17qI2-q21. Nat Genet 1996;13:461-3.
43. McDonald JM, Douglass EC, Fisher R, et al. Linkage of Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 1998; 58:1387-90.
44. Choyke PL, Siegel MJ, Craft AW, et al. Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy. Med Pediatr Oncol 1999; 32:196-200.
45. McNeil DE, Brown M, Ching A, et al. Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model. Med Pediatr Oncol 2001;37:349-56.
46. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome? Ann Intern Med 1969;71:747-51.
47. Li FP, Fraumeni J, Mulvihill J. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
48. Garber J, Goldstein AK, Dreyfus M, et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:6049-97.
49. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
50. Malkin D, Jolly K, Barbier N, et al. Germline mutations of the p53 tumor suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992;326:1309-15.
51. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994;86:1707-10.
52. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
53. Patenaude AF. The genetic testing of children for cancer susceptibility: ethical, legal and social issues. Behav Sci Law 1996;14:393-410.
54. Li FP, Garber JE, Friend SH, et al. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992;84:1156-60.
55. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutation of IN11 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-9.
56. Savla J, Chen T, Schneider NR, et al. Mutations of the hSNF5/IN11 gene in renal rhabdoid tumors with second primary brain tumors. J Natl Cancer Inst 2000;92:648-50.
57. Friedrich CA. Von Hippel-Lindau syndrome: a pleomorphic condition. Cancer 1999;86(Suppl):2478-82.
58. Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001;46:117-42.
59. Maddock IR, Moran A, Maher ER, et al. A genetic register for von Hippel-Lindau disease. J Med Genet 1996;33:120-7.
60. Latif F, Tory K, Gnarra J, et al. Identification of the von Hipple-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
61. Kaelin WG, Iliopoulos O, Lonergan M, et al. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 1998;243:535-9.
62. Kondo K, Kaelin WG. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-25.
63. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hipple-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
64. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hipple-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
65. Olschwang S, Richard S, Boisson C, et al. Germline mutation profile of the VHL gene in von Hipple-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 1998;12:424-30.
66. Bar M, Friedman E, Jakobovitz O, et al. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hipple-Lindau and RET genes. Clin Endocrinol (Oxf) 1997;47:707-12.
67. Sgambati MT, Stolle C, Choyke PL, et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 2000;66:84-91.
68. Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 1990;46:9-19.
69. Lang E, Borresen AL, Chen X, et al. Localization of an ataxia-telangiectasia gene to a ∼500 kb interval on chromosome 11q23.1: linkage analysis of 176 families in an international consortium. Am J Hum Genet 1995;57:112-9.
70. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
71. Meyn MS. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 1999;55:289-304.
72. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxiatelangiectasia. J Natl Cancer Inst 1986;77:89-92.
73. Murphy RC, Berdon WE, Ruzal-Shapiro C, et al. Malignancies in pediatric patients with ataxiatelangiectasia. Pediatr Radiol 1999;29:225-30.
74. Swift M, Morrell D, Massey RB. Incidence of cancer in 161 families affected by ataxiatelangiectasia. N Engl J Med 1991;325:1831-6.
75. German J. Bloom's syndrome. Dermatol Clin 1995;13:7-18.
76. German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997;93:100-6.
77. German J, Crippa LP, Bloom D. Bloom's syndrome. III. Analysis of the chromosome aberration characteristic of this disorder. Chromosoma 1974;48:361-6.
78. Poppe B, Van Limbergen H, Van Roy N, et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet 2001;128:39-42.
79. Ellis NA, Gorden J, Ye TZ, et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 1995;83:655-66.
80. Kitao S, Shimamoto A, Goto M, et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 1999;22:82-4.
81. Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001;102:11-7.
82. Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996;272:258-62.
83. Miller M. Werner's syndrome: what does an aging syndrome gene reveal about cancer? J Natl Cancer Inst 1999;91:589-90.
84. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997;276:404-7.
85. Easton DF, Ponder MA, Cummings T. The clinical and screening age-of-onset distribution for the MEN-2 syndrome. Am J Hum Genet 1989;44:208-15.
86. Carney JA, Sizemore GW, Lovestedt SA. Mucosal ganglioneuromatosis, medullary thyroid carcinoma, and pheochromocytoma: multiple endocrine neoplasia, type 2b. Oral Surg 1976; 41:739-52.
87. Brown RS, Colle E, Tashjian AH. The syndrome of multiple mucosal neuromas and medullary thyroid carcinoma in children. J Pediatr 1975;86:77-83.
88. Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-81.
89. Mulligan LM, Kwok JBJ, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
90. Hofstra RMW, Lansvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
91. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996;276:1575-9.
92. Graze K, Spiler IJ, Tashjian AH, et al. Natural history of familial medullary thyroid carcinoma. N Engl J Med 1978;299:980-5.
93. Telander RL, Zimmerman D, Sizemore GW, et al. Medullary carcinoma in children: results of early detection and surgery. Arch Surg 1989;124:841-3.
94. Van Heurn E, Schaap C, Sie G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 1999;34:568-71.
95. Lynch PM. COX-2 inhibition in clinical cancer prevention. Oncology 2001;15:21-6.
96. Jagelman DG. Extracolonic manifestations of familial polyposis coli. Semin Surg Oncol 1987;3:88-91.
97. Gardner EJ, Richards RC. Multiple cutaneous and subcutaneous lesions occurring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953;5:139-47.
98. Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumours in familial adenomatous polyposis. Gut 1994;3:377-81.
99. Tiret A, Taiel-Sartral M, Tiret E, et al. Diagnostic value of fundus examination in familial adenomatous polyposis. Br J Ophthalmol 1997;81:755-8.
100. Giardiello FM, Lee DH, Krush AJ, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;34:1394-6.
101. Turcot J, Despres JP, St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 1959; 2:465-8.
102. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-46.
103. Herrera L, Kakati S, Gibas L, et al. Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 1986;25:473-6.
104. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987;328:614-6.
105. Leppert M, Dobbs M, Scambler P, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987;238:1411-3.
106. Nagase H, Miyoshi Y, Horii A, et al. Correlation between the location of germline mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 1992;52:4055-7.
107. Brensinger JD, Laken SJ, Luce MC, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 1998;43:548-52.
108. Hyer W, Fell JM. Screening for familial adenomatous polyposis. Arch Dis Child 2001;84:377-80.
109. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
110. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93:1496-501.
111. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89:1701-7.
112. Wiemels JL, Smith RM, Taylor GM, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A 2001;98:4004-9.
113. Chakraverty RK, Hickson ID. Defending genome integrity during DNA replication: a proposed role for RecQ family helicases. Bioessays 1999;21:286-94.
114. Giardiello FM, Offerhaus JA, Krush AJ, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr 1991;119:766-8.
115. Gruner BA, DeNapoli TS, Andrews W, et al. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol 1998; 20:274-8.
116. Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989;44:711-9.
117. Swift M, Reitnauer PJ, Morrell D, et al. Breast and other cancers in families with ataxiatelangiectasia. N Engl J Med 1987;316:1289-94.
118. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326:1301-8.
119. Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001:95(2):102-7.